Table 9.
Sensitivity analysis results for the impact of each parameter on cost-effectiveness
| Parameter | Change | New value | Total cost (TL) | YLL | Cost difference (TL) | Year difference | ||
|---|---|---|---|---|---|---|---|---|
| Age = 50 years | 50 | TDF | 119,604 | 1.302 | ||||
| ETV-TDF | 161,642 | 1.347 | 42,037 | 0.045 | ||||
| ETV | 162,115 | 1.347 | 42,511 | 0.046 | ||||
| LdT-TDF | 138,182 | 1.923 | 18,577 | 0.622 | ||||
| 3TC-TDF | 132,157 | 2.028 | 12,552 | 0.726 | ||||
| LdT | 151,059 | 2.581 | 31,455 | 1.280 | ||||
| 3TC | 147,245 | 4.109 | 27,640 | 2.807 | ||||
| TDF | 119,604 | 2.987 | ||||||
| ETV-TDF | 161,642 | 3.088 | 42,037 | 0.101 | ||||
| ETV | 162,115 | 3.089 | 42,511 | 0.102 | ||||
| Age = 30 years | 30 | LdT-TDF | 138,182 | 4.429 | 18,577 | 1.442 | ||
| 3TC-TDF | 132,157 | 4.621 | 12,552 | 1.634 | ||||
| LdT | 151,059 | 5.954 | 31,455 | 2.967 | ||||
| 3TC | 147,245 | 9.453 | 27,640 | 6.465 | ||||
| TDF | 119,411 | 2.025 | ||||||
| ETV-TDF | 161,353 | 2.079 | 41,943 | 0.054 | ||||
| ETV | 161,826 | 2.079 | 42,416 | 0.055 | ||||
| HBeAg (−) rate | 25 % increase | 88 % | LdT-TDF | 132,215 | 2.656 | 12,804 | 0.631 | |
| 3TC-TDF | 127,731 | 2.907 | 8320 | 0.882 | ||||
| LdT | 137,643 | 3.152 | 18,233 | 1.128 | ||||
| 3TC | 128,004 | 5.124 | 8593 | 3.099 | ||||
| TDF | 119,798 | 2.096 | ||||||
| ETV-TDF | 161,930 | 2.183 | 42,132 | 0.087 | ||||
| ETV | 162,404 | 2.183 | 42,606 | 0.088 | ||||
| HBeAg (−) rate | 25 % decrease | 53 % | LdT-TDF | 144,149 | 3.445 | 24,351 | 1.349 | |
| 3TC-TDF | 136,582 | 3.487 | 16,784 | 1.391 | ||||
| LdT | 164,475 | 5.045 | 44,677 | 2.949 | ||||
| 3TC | 166,486 | 7.907 | 46,688 | 5.811 | ||||
| TDF | 119,573 | 2.055 | ||||||
| ETV-TDF | 161,642 | 2.131 | 42,068 | 0.076 | ||||
| ETV | 162,115 | 2.131 | 42,542 | 0.076 | ||||
| TDF: virologic response 48th week in HBeAg (−) | 25 % increase | 100.0 % | LdT-TDF | 138,176 | 3.049 | 18,603 | 0.994 | |
| 3TC-TDF | 132,148 | 3.196 | 12,574 | 1.140 | ||||
| LdT | 151,059 | 4.099 | 31,486 | 2.043 | ||||
| 3TC | 147,245 | 6.515 | 27,672 | 4.460 | ||||
| TDF | 119,711 | 2.078 | ||||||
| ETV-TDF | 161,642 | 2.131 | 41,931 | 0.053 | ||||
| ETV | 162,115 | 2.131 | 42,404 | 0.053 | ||||
| TDF: Virologic response 48th week in HBeAg (−) | 25 % decrease | 69.9 % | LdT-TDF | 138,202 | 3.054 | 18,491 | 0.976 | |
| 3TC-TDF | 132,186 | 3.202 | 12,475 | 1.124 | ||||
| LdT | 151,059 | 4.099 | 31,348 | 2.021 | ||||
| 3TC | 147,245 | 6.515 | 27,534 | 4.437 | ||||
| TDF | 119,538 | 2.049 | ||||||
| ETV-TDF | 161,642 | 2.131 | 42,103 | 0.082 | ||||
| ETV | 162,115 | 2.131 | 42,577 | 0.082 | ||||
| TDF: Virologic response 48th week in HBeAg (+) | 25 % increase | 95.2 % | LdT-TDF | 138,153 | 3.044 | 18,614 | 0.996 | |
| 3TC-TDF | 132,118 | 3.190 | 12,580 | 1.141 | ||||
| LdT | 151,059 | 4.099 | 31,521 | 2.050 | ||||
| 3TC | 147,245 | 6.515 | 27,707 | 4.467 | ||||
| TDF | 119,671 | 2.072 | ||||||
| ETV-TDF | 161,642 | 2.131 | 41,971 | 0.059 | ||||
| ETV | 162,115 | 2.131 | 42,444 | 0.060 | ||||
| TDF: Virologic response 48th week in HBeAg (+) | 25 % decrease | 57.1 % | LdT-TDF | 138,211 | 3.056 | 18,540 | 0.985 | |
| 3TC-TDF | 132,195 | 3.204 | 12,524 | 1.133 | ||||
| LdT | 151,059 | 4.099 | 31,388 | 2.027 | ||||
| 3TC | 147,245 | 6.515 | 27,574 | 4.444 | ||||
| TDF | 140,826 | 2.060 | ||||||
| ETV-TDF | 161,879 | 2.131 | 1053 | 0.070 | ||||
| ETV | 162,115 | 2.131 | 1289 | 0.071 | ||||
| TDF annual drug cost | 25 % decrease | 2796 TL | LdT-TDF | 144,943 | 3.050 | 4117 | 0.990 | |
| 3TC-TDF | 147,174 | 3.197 | 6348 | 1.137 | ||||
| LdT | 151,059 | 4.099 | 0233 | 2.038 | ||||
| 3TC | 147,245 | 6.515 | 6419 | 4.455 | ||||
| TDF | 98,383 | 2.060 | ||||||
| ETV-TDF | 161,405 | 2.131 | 63,022 | 0.070 | ||||
| ETV | 162,115 | 2.131 | 63,732 | 0.071 | ||||
| TDF annual drug cost | 25 % decrease | 1677 TL | LdT-TDF | 131,421 | 3.050 | 33,038 | 0.990 | |
| 3TC-TDF | 117,139 | 3.197 | 18,756 | 1.137 | ||||
| LdT | 151,059 | 4.099 | 52,676 | 2.038 | ||||
| 3TC | 147,245 | 6.515 | 48,862 | 4.455 |
Tenofovir dominates all comparisons in all scenarios